Market Cap 1.95B
Revenue (ttm) 336.89M
Net Income (ttm) -87.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26.10%
Debt to Equity Ratio 0.00
Volume 524,500
Avg Vol 508,856
Day's Range N/A - N/A
Shares Out 49.45M
Stochastic %K 59%
Beta 1.00
Analysts Strong Sell
Price Target $64.80

Latest News on MIRM

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Apr 14, 2025, 8:30 AM EDT - 10 days ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation


LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 27, 2025, 8:30 AM EDT - 4 weeks ago

LIVMARLI Now Approved in Japan for ALGS and PFIC


US FDA approves Mirum Pharma's genetic disorder drug

Feb 21, 2025, 12:01 PM EST - 2 months ago

US FDA approves Mirum Pharma's genetic disorder drug


Mirum Pharma: Buy At Dips For Volixibat Potential

Dec 25, 2024, 10:00 AM EST - 4 months ago

Mirum Pharma: Buy At Dips For Volixibat Potential


3 Biotech Stocks For The Second Half Of 2024

Jun 27, 2024, 4:48 PM EDT - 10 months ago

3 Biotech Stocks For The Second Half Of 2024

ALT NTLA


US FDA approves expanded use of Mirum's liver disease drug

Mar 13, 2024, 6:49 PM EDT - 1 year ago

US FDA approves expanded use of Mirum's liver disease drug


Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 5, 2024, 5:29 AM EST - 1 year ago

Mirum Pharmaceuticals: Advancing On Several Key Fronts